EX-99.2 3 tm2630146d1_ex99-2.htm EXHIBIT 99.2

Exhibit 99.2

 

CytoSorbents Corporation Nasdaq: CTSO Q3 2026 Earnings Conference Call November 12, 2026 (Updated November 19, 2026 – see Explanatory Note)

 

 

This presentation was originally used in connection with the CytoSorbents Corporation third quarter 2026 earnings conference call held on November 12 , 2026 . It has been updated, and is being furnished as an exhibit to the Company’s Current Report on Form 8 - K/A filed with the U . S . Securities and Exchange Commission (“SEC”) on November 19 , 2026 , to reflect revisions to the loss on foreign currency transactions and related amounts reported in the Company’s Quarterly Report on Form 10 - Q for the quarter ended September 30 , 2026 , filed with the SEC on the same date . The updated press release is also included in the Form 8 - K/A . Updated amounts appear on slides 10 , 11 and 24 . Third quarter 2026 net loss is $ 2 . 1 million (previously $ 1 . 8 million) and nine - month 2026 net loss is $ 12 . 0 million (previously $ 11 . 4 million), with related changes to EBITDA and to the reconciliation of non - GAAP financial measures . Growth in direct sales outside Germany has also been conformed to 5 % (previously 4 % ) on slides 9 , 14 and 21 . These revisions are non - cash and do not affect previously reported revenue, gross profit, operating expenses, loss from operations, third quarter Adjusted EBITDA, or cash . Except as described above, this presentation speaks as of November 12 , 2026 , and the Company has not updated it for events or information arising after that date . Explanatory Note 2

 

 

Conference Call Participants Phillip Chan, MD, PhD Chief Executive Officer Peter J. Mariani, CPA Chief Financial Officer 3

 

 

Statements in this presentation include forward - looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995 . These forward - looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward - looking statements are expressed differently . You should be aware that the forward - looking statements in this presentation represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward - looking statements . Factors which could cause or contribute to such differences include, but are not limited to, our restructuring of our direct sales team and strategy in Germany, our ability to successfully obtain U . S . FDA and Health Canada marketing authorization or approval, our ability to sustain operating cash - flow break - even, our ability to regain and maintain compliance with Nasdaq continued listing requirements, our ability to appropriately finance the Company, including the extension, refinancing or repayment of our existing debt, our ability to develop and commercialize our products and product candidates including securing necessary funding and strategic partnerships, our ability to attract, retain and effectively integrate qualified personnel to support our business and growth objectives, and the risks discussed in our Annual Report on Form 10 - K, filed with the SEC on March 30 , 2026 , as updated by the risks reported in our Quarterly Reports on Form 10 - Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business . We caution you not to place undue reliance upon any such forward - looking statements . We undertake no obligation to publicly update or revise any forward - looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws . Safe Harbor Statement 4 About Non - GAAP Financial Measures To supplement our condensed consolidated financial statements, we use the non - GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, and Adjusted EBITDA which further excludes non - cash stock compensation expense, the gain or loss of foreign exchange translation, and restructuring charges . We also use the non - GAAP financial measures of Adjusted Net Income or Loss and Adjusted Net Income or Loss Per Share which excludes non - cash stock compensation expense, the gain or loss of foreign exchange translation, and restructuring charges from Net Loss and Net Loss Per Share, respectively . Additionally, we use the non - GAAP financial measure of Negative Free Cash Flow which consists of net cash used in operating activities plus net cash used in investing activities . These non - GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non - GAAP measures used by other companies . In addition, these non - GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP . The reconciliations of the non - GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated . We use these non - GAAP financial measures for financial and operational decision - making and as a means to evaluate period - to - period comparisons . We believe that these non - GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non - GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods . We believe these non - GAAP financial measures are useful to investors because ( 1 ) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision - making and ( 2 ) they are used by investors and the analyst community to help them analyze the performance of our business, the Company’s cash available for operations, and the Company’s ability to meet future capital expenditure and working capital requirements . For a reconciliation of non - GAAP financial measures to the most comparable GAAP measure, see the reconciliation included in the financial tables . All non - GAAP adjustments are presented pre - tax .

 

 

Operational Update Dr. Phillip Chan, MD, PhD Chief Executive Officer 5

 

 

75% Gross Margin Achieved operating cash flow breakeven, the first of four distinct value drivers • Gross margin expanded to 75%, up from 73% in Q2 2026 and 70% in Q3 2025 • Operating expenses down 11%; adjusted EBITDA loss narrowed 86% • Year - to - date cash used in operations down 73% to $2.0M • Advancing DrugSorb - ATR toward a new De Novo submission in early 2027 $9.7M Q3 2026 Revenue +$43K Operating Cash Flow* * Excluding ~$251K of restructuring - related payments. Q3 2026: A Financial Milestone 6

 

 

Four Distinct Drivers of Value Creation 7 ✓ Achieved

 

 

Financial Highlights and Value Driver #1 Achieved Operating Cash Flow Breakeven Peter J. Mariani Chief Financial Officer | 8 ✓ Achieved

 

 

YoY Change Q3 2026 +3% $9.7m Revenue: +18% $5.1m Distributors and Strategic Partners +5% $2.4m Direct Intl - 21% $2.3m Germany • Growth led by distributor and strategic partner sales, up 18 % year - over - year • Direct sales outside Germany up 5 % year - over - year • Germany down 21 % , reflecting reduced territory coverage after our commercial restructuring ; sales team being rebuilt • Revenue up 1 % sequentially from Q 2 2026 | 9 Q3 2026 Revenue

 

 

Q3 2026 Performance Margin expansion and cost discipline cut adjusted EBITDA loss 86% | 10 Revenue $9.7M ▲ 3% vs. $9.5M in Q3 2025 Gross margin 75% ▲ 5 pts vs. 70% in Q3 2025 Operating expenses $8.5M ▼ 11% vs. $9.5M in Q3 2025 Operating loss ($1.2M) 59% improvement vs. ($2.9M) in Q3 2025 Net loss ($2.1M) 35% improvement vs. ($3.2M) in Q3 2025 Adjusted EBITDA loss* ($0.3M) 86% improvement vs. ($2.0M) in Q3 2025 Adjusted EBITDA loss by quarter* 2026, $ millions ($2.1M) ($1.6M) ($0.3M) Q1 2026 Q2 2026 Q3 2026 Improved every quarter of 2026 * Non - GAAP measure; see the reconciliation in the appendix. Quarterly figures rounded .

 

 

9 - month 2026 Performance Adjusted EBITDA loss improved 45% on higher margins and lower costs | 11 Revenue $28.2M ▲ 1% vs. $27.8M in 9M 2025 Gross margin 73% ▲ 2 pts vs. 71% in 9M 2025 Operating expenses $27.4M ▼ 9% vs. $30.1M in 9M 2025 Operating loss ($6.9M) 34% improvement vs. ($10.4M) in 9M 2025 Net loss ($12.0M) Reflects FX swing vs. ($2.7M) in 9M 2025 Adjusted EBITDA loss* ($4.0M) 45% improvement vs. ($7.3M) in 9M 2025 Operating loss improved 34% $3.5M better: ($6.9M) vs. ($10.4M) Key drivers (favorable impact) Higher gross profit (72.7% margin) +$0.8M Lower selling, travel and marketing +$1.1M Lower compensation (workforce plan) +$1.0M Lower legal, financial and consulting +$0.8M Lower R&D, including clinical studies +$0.2M Partly offset by $0.6M of restructuring charges * Non - GAAP measure; see the reconciliation in the appendix. Net loss includes an $11.7M swing in non - cash foreign currency ($2.5 M loss in 9M 2026 vs. $9.1M gain in 9M 2025).

 

 

• +$43K operating cash flow in Q3, excluding ~$251K of restructuring - related payments • Total Q3 cash burn of ~$0.2M; $5.7M of cash, cash equivalents and restricted cash at September 30 • Year - to - date cash used in operations down 73% to $2.0M • Focus now shifts to remaining at or near breakeven; quarterly results may fluctuate with timing of revenue, collections and working capital • Actively working to satisfy the remaining Nasdaq listing requirement and debt restructuring by the end of this year Operating Cash Flow Breakeven Achieved in Q3 2026 * Negative Free Cash Flow = Net cash used in operating activities plus net cash used in investing activities ($7,000) ($6,000) ($5,000) ($4,000) ($3,000) ($2,000) ($1,000) $0 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Amount ($ thousands) Negative Free Cash Flow by Quarter (Q3 2023 - Q3 2026) Fundamental improvements drive breakeven | 12

 

 

Value Driver #2: Driving Core CytoSorb Sales Growth Dr. Phillip Chan, MD, PhD Chief Executive Officer 13 CytoSorb is approved in the EU but is not yet cleared or approved i n the U.S. and Canada

 

 

+5% Direct Intl Growing markets are 77% of sales; restoring growth in Germany is a top priority • Two new German sales representatives added; one more next month and two more by early 2027 • Alex Tiefenbacher joined as SVP of Direct Sales (C.R. Bard, Becton Dickinson, GE Healthcare, Baxter) • “Right Patient, Right Time, Right Dose” strategy gaining traction with PuriFi® and HotSwap® • Expanding clinical evidence, including EACTS 2026 and COSMOS registry data at ESICM LIVES 2026 +1 8 % Distributors* - 2 1 % Germany * Distributor and strategic partner sales. All growth rates are Q3 2026 vs. Q3 2025 . Returning CytoSorb to Growth 14

 

 

Value Driver #3: Opening the U.S. Market Through DrugSorb - ATR Dr. Phillip Chan, MD, PhD Chief Executive Officer 15 DrugSorb - ATR is an investigational device in th e U.S. and Canada and not yet cleared/approved

 

 

~8 NNT** Two distinct potential pathways to U.S. commercialization • Brilinta® (ticagrelor): new De Novo submission planned for early 2027, with ~5x more treated patients • ESC data also showed less chest tube drainage and fewer transfusions, with no serious device - related AEs • After a constructive August pre - sub, finalizing an animal study protocol with FDA for mechanistic data • DOACs (Eliquis®, Xarelto®): separate De Novo submission expected in 2027 • Initial U.S. and Canada market of ~$300M, expandable to $1 – 2B with label expansion 37% Less Bleeding* ~250 Patients in Submission * Severe (BARC - 4) bleeding, 21.8% vs. 34.5% (p=0.002); 587 urgent CABG patients, ESC 2026. ** Number needed to treat. DrugSorb - ATR is investigational in the U.S. and Canada and not yet cleared/approved. DrugSorb - ATR: Path to Approval 16

 

 

Dr. Phillip Chan, MD, PhD Chief Executive Officer Value Driver #4: Unlocking the Strategic Value of HemoDefend - BGA | 17

 

 

HemoDefend - BGA: Unlocking Strategic Value • Simple, gravity - driven filter that removes anti - A and anti - B antibodies to enable universal plasma and platelets • No electricity, capital equipment or complex processing required • Could simplify blood bank inventories to one universal plasma and one universal platelet product • Longer term, could enable freeze - dried universal plasma for first responders and the military, with no refrigeration or blood typing • Developed with ~$16M of prior non - dilutive U.S. government funding • Constructive FDA feedback on our anticipated clinical pathway in July 2026 • Pursuing non - dilutive funding, commercial partnerships, licensing and other strategic alternatives Potential to unlock shareholder value without substantial investment from our core operations | 18

 

 

Closing Remarks Phillip Chan, MD, PhD Chief Executive Officer | 19

 

 

Four Distinct Value Drivers. One Uncommon Value | 20 ✓ Achieved

 

 

Value Driver Scorecard | 21 What's Next Q3 2026 Progress Value Driver Sustain at or near breakeven; selectively invest in sales growth ✓ Achieved: +$43K operating cash flow*; adjusted EBITDA loss down 86% 1. Operating Cash Flow Breakeven Rebuild German sales force (5 new reps by early 2027) under new SVP of Direct Sales Distributors +18%, Direct Intl +5% (together 77% of sales); Germany −21% 2. Core CytoSorb Sales Growth Brilinta® De Novo in early 2027; separate DOAC De Novo in 2027 ESC 2026: 37% less severe bleeding in 587 urgent CABG patients; constructive FDA pre - subs 3. U.S. Market with DrugSorb - ATR Pursue non - dilutive funding, partnerships, licensing and other alternatives Constructive FDA feedback on clinical pathway (July 2026) 4. Strategic Value of HemoDefend - BGA * Excluding ~$251K of restructuring - related payments. Growth rates are Q3 2026 vs. Q3 2025. DrugSorb - ATR is investigational in t he U.S. and Canada and not yet cleared/approved.

 

 

Company Contacts: Dr. Phillip Chan - CEO [email protected] Peter Mariani – CFO [email protected] Q&A Session NASDAQ: CTSO 22

 

 

Appendix Reconciliation of non - GAAP Financial Measures | 23

 

 

Reconciliation of Non - GAAP Financial Measures | 24 9M 2025 9M 2026 Q3 2025 Q3 2026 ($ thousands, except per share) (2,701) (12,005) (3,170) (2,054) Net loss 1,137 1,043 364 344 Depreciation and amortization (401) — (401) — Income tax benefit 1,866 2,618 645 892 Interest expense, net (99) (8,344) (2,562) (818) EBITDA 1,879 1,203 488 291 Non - cash stock - based compensation (9,128) 2,534 64 (7) (Gain) loss on foreign currency transactions — 562 — 250 Restructuring (7,348) (4,045) (2,010) (284) Adjusted EBITDA (2,701) (12,005) (3,170) (2,054) Net loss 1,879 1,203 488 291 Non - cash stock - based compensation (9,128) 2,534 64 (7) (Gain) loss on foreign currency transactions — 562 — 250 Restructuring (9,950) (7,706) (2,618) (1,520) Adjusted net loss ($3.21) ($2.45) ($0.83) ($0.48) Adjusted net loss per share